Dr. Deitcher is an innovative business leader who has more than 25 years of life science product development experience including cellular therapeutics, biologics, small molecules, and diagnostics. He was President, CEO and Board Member at Talon Therapeutics, a specialty biopharmaceutical company focused on novel cancer drug delivery. At Talon, his team advanced its lead compound, Marqibo®, from IND to FDA accelerated approval to treat leukemia and positioned the company for sale to Spectrum Pharmaceuticals. He previously served as Vice President and Chief Medical Scientist at Nuvelo. He was formerly the Chief of Hematology and Director of Thrombosis and Vascular Medicine Research at The Cleveland Clinic and held leadership positions at The University of Tennessee Health Science Center and St. Jude Children’s Research Hospital.
He received his B.S. and M.D. in the Honors Program in Medical Education at Northwestern University. He is a member of several corporate and university advisory boards and has authored 225 publications in medical and scientific journals.
Dr. Weber joined Medeor Therapeutics in 2016 to lead all global regulatory and quality efforts related to MDR-101. He has more than 20 years of regulatory affairs experience with biological products. Previously, he was Executive Vice President of Global Regulatory Affairs and Quality Management for Mesoblast LTD. Prior to joining Mesoblast, he worked as a Senior Consultant at Biologics Consulting Group, specializing in stem cell and regenerative medicine products. Prior to becoming an industry consultant, he spent over seven years at the U.S. Food and Drug Administration, Center for Biologics Evaluation and Research where he served as Chief, Cellular Therapy Branch in the then newly created Office of Cellular, Tissue and Gene Therapies. During his time at FDA, he was actively involved in the development of policies and guidance documents for cellular and tissue-based products.
Dr. Weber received a B.S. in molecular biology from The Evergreen State College and a Ph.D. in biochemistry and biophysics from Oregon State University. Dr. Weber is an active participant on a number of advisory and standard-setting committees for cell-based medicines, including the UP Pharmacopoeia (USP), California Institute for Regenerative Medicine (CIRM), and International Society for Cell Therapy (ISCT).
Dr. Read joined Medeor Therapeutics in 2015 to lead MDR-101 product development efforts ranging from donor stem cell collection to commercial manufacturing and final product delivery to patients. She has more than 20 years of product development experience with biological products. Previously, Dr. Read held cell therapy industry leadership roles including Chief Medical Officer at StemCyte and Head of Product development at Fate Therapeutics. Prior to joining industry, she directed the cell and tissue therapies program at Blood Systems Research Institute affiliated with UCSF and served as Section Chief and Medical Director of the Cell Therapy Core Facility at the National Institutes of Health (NIH) Clinical Center. Prior to NIH, she was the Medical Director at the American Red Cross Blood & Tissue Services for the Southern California region.
Dr. Read received an A.B. from Bryn Mawr College and M.D. from SUNY Buffalo. She has authored 99 scientific publications and served on numerous advisory and standard-setting committees focused on blood products and cell, tissue, and gene therapies, including several US Pharmacopoeia (USP) Biologics & Biotechnology expert committees.
Dr. Batty joined Medeor Therapeutics in 2016 as Chief Medical Officer to lead the clinical development and medical affairs efforts related to Medeor's organ transplantation programs. Previously, Scott held an executive management role at ImmunArray as well as leadership roles in transplant and stem cell product clinical development and medical affairs at Genzyme (a Sanofi company) and Bristol-Myers Squibb. He played key roles in the development of Thymoglobulin®, Nulojix®, and Mozobil®. Before joining industry, Dr. Batty was a leading academic multi-organ transplant surgeon at Walter Reed Army Medical Center, Georgetown University Hospital, and the National Institutes of Health in the Washington, DC area.
Dr. Batty received his B.S. in Chemistry and M.D. from Tufts University. He trained in General Surgery at Walter Reed Army Medical Center and in Multi-Organ Transplant Surgery at the University of Pittsburgh. Prior to transitioning to industry, Dr. Batty held leadership roles in the Washington DC area organ procurement organization and worked extensively with local donor awareness and family support groups.
Matthew J. Plunkett assumed his role as our Chief Financial and Business Officer in September 2017. He is responsible for all finance and corporate development functions at the Company. Previously he served at CTI BioPharma from September 2012 to August 2017, most recently as Executive Vice President, Chief Business Officer. Dr. Plunkett previously served as Chief Financial Officer of the California Institute for Regenerative Medicine from November 2011 to August 2012. From July 2009 to April 2011, Dr. Plunkett was the Vice President and Chief Financial Officer of iPerian, Inc. From December 2000 to July 2009, Dr. Plunkett held positions at Oppenheimer & Co. and its U.S. predecessor, CIBC World Markets, including serving as Managing Director, Head of West Coast Biotechnology from December 2008 to July 2009, and Executive Director, Head of West Coast Biotechnology from January 2008 to December 2008.
Matthew received his B.S. in chemistry from Harvey Mudd College and a Ph.D. in organic chemistry from the University of California, Berkeley.